New Molecular Targets Are Reshaping Personalized Treatment of Low-Grade Non-Hodgkin Lymphoma

The treatment of low-grade non-Hodgkin lymphoma is undergoing a quiet but profound transformation. For decades, the standard of care for these slow-growing cancers of the lymphatic system revolved around conventional chemoimmunotherapy, a blunt but effective approach that treated most patients with broadly similar regimens. Today, that picture is changing rapidly. Driven by advances in molecular biology, genomic profiling, and cancer immunology, clinicians are increasingly able to match therapies to the specific molecular and genomic characteristics of each patient’s disease. A recent Research Topic published in Frontiers in Hematology, assembled by Andrea Visentin of the University of Padova, brings together six studies that chart this shift from one-size-fits-all treatment toward true precision medicine, spanning original laboratory research, clinical reviews, a case report, and novel prognostic modeling.

The central premise of the collection is that understanding lymphoma biology at the molecular level is the key to improving outcomes. Despite a decade of progress, low-grade lymphomas remain incurable with conventional approaches for most patients, and disease heterogeneity, therapeutic resistance, and relapse continue to frustrate clinicians. The six contributions, three focused on low-grade lymphomas and three on aggressive subtypes, share a common objective: deepening the mechanistic understanding of these cancers in ways that translate directly into individualized therapeutic interventions. The breadth of topics covered illustrates how many different layers of biology, from epigenetics to inflammation, must be understood before personalized treatment can become routine.

One of the most technically intriguing contributions is an original research article investigating dual targeting of EZH2 and PD-L1 in Burkitt’s lymphoma. EZH2 is a histone methyltransferase, an enzyme that chemically modifies histone proteins around which DNA is wound, thereby controlling which genes are accessible for transcription. In many B-cell malignancies, EZH2 activity is dysregulated, locking cells into abnormal gene-expression programs that promote survival and proliferation. PD-L1, meanwhile, is an immune checkpoint molecule that tumor cells display to suppress T-cell activity, effectively camouflaging the cancer from the immune system. The researchers demonstrated that inhibiting both targets simultaneously produces synergistic antitumor activity: apoptosis, or programmed cell death, increases within the tumor, while immune activation is restored. Although Burkitt lymphoma is an aggressive disease rather than a low-grade subtype, the underlying mechanism is broadly applicable across low-grade B-cell lymphomas. The findings lend strong support to the concept that epigenetic remodeling can enhance immune-mediated tumor elimination, providing a rationale for combining targeted epigenetic drugs with immunotherapy.

Waldenström macroglobulinemia, an indolent B-cell malignancy, serves as a striking example of how precision medicine is already changing clinical practice. A review article on relapsed or refractory disease summarizes how treatment selection increasingly depends on the molecular profile of the tumor, particularly mutations in MYD88 and CXCR4, two genes that drive signaling through the B-cell receptor pathway and related networks. Patients harboring different mutational patterns respond differently to available drugs, making genetic testing central to therapeutic planning. The review surveys an expanding armamentarium: next-generation Bruton tyrosine kinase inhibitors designed to improve on first-generation covalent BTK blockers, BCL2 inhibition that targets the anti-apoptotic machinery keeping lymphoma cells alive, CXCR4-targeted agents, bispecific antibodies that bridge immune cells to tumor cells, antibody-drug conjugates that deliver cytotoxic payloads selectively, and chimeric antigen receptor T-cell therapy. Beyond cataloguing these drugs, the authors emphasize individualized treatment selection, therapeutic sequencing, and biomarker-guided decision-making, reflecting the growing complexity of managing indolent B-cell cancers.

The clinical potential of innovative immunotherapy combinations is illustrated in a case report describing a patient with relapsed or refractory central nervous system lymphoma successfully treated with glofitamab combined with lenalidomide. Glofitamab is a CD20×CD3 bispecific antibody, a engineered molecule with one arm binding the CD20 protein on B cells and the other binding CD3 on T cells, physically bringing cytotoxic T lymphocytes into contact with malignant cells. Lenalidomide is an immunomodulatory agent that alters the tumor microenvironment and enhances immune function. Lymphoma relapsing in the central nervous system is particularly difficult to treat, as many drugs fail to cross the blood-brain barrier and intensive chemotherapy carries substantial toxicity. The favorable response observed, though based on limited clinical experience, demonstrates the promise of chemotherapy-free strategies that engage the immune system to achieve durable disease control while potentially sparing patients the burden of toxic regimens. The report provides valuable preliminary evidence supporting formal clinical evaluation of bispecific antibody-based combinations.

Treatment resistance remains one of the greatest barriers to successful targeted therapy, and a mini-review on kinase inhibitor resistance in subtypes of cutaneous T-cell lymphoma confronts this problem directly. Kinase inhibitors block specific signaling enzymes that lymphoma cells depend on, but tumors frequently find ways around them. The review describes how genetic mutations, activation of compensatory signaling pathways that bypass the blocked enzyme, epigenetic alterations that reprogram gene expression, and changes within the tumor microenvironment collectively contribute to therapeutic failure. The authors argue that understanding these resistance mechanisms is essential for designing rational combination therapies capable of restoring treatment sensitivity. Although focused on a T-cell malignancy, the concepts have broad relevance across lymphoma subtypes and underscore resistance biology as a critical frontier in precision hematology, where the sequence and combination of drugs must anticipate the escape routes available to the tumor.

Personalized medicine extends beyond treatment to diagnosis and clinical evaluation, as highlighted by an unusual case report of synchronous mucosa-associated lymphoid tissue lymphoma occurring in a married couple. MALT lymphoma arises in lymphoid tissue associated with mucosal surfaces and is often linked to chronic inflammation or infection. The simultaneous development of this rare lymphoma in spouses cannot establish causality, but it raises intriguing questions about shared environmental exposures, infectious agents, or other common risk factors that might contribute to lymphoma pathogenesis. The report also emphasizes the importance of comprehensive diagnostic assessment in atypical clinical presentations and demonstrates how rare observations can generate hypotheses that stimulate future biological and epidemiological research, a reminder that careful clinical documentation remains a source of scientific discovery.

Accurate prognostic assessment forms another essential pillar of personalized care. A study addressing grade 1–3a follicular lymphoma integrated the systemic immune-inflammation index, a blood-based measure derived from routine counts of immune cells that reflects the balance of systemic inflammation, with the established Follicular Lymphoma International Prognostic Index. The investigators proposed a novel combined model, FLIPI-SII, that improves prediction of POD24, meaning progression of disease within 24 months of treatment, as well as long-term survival. POD24 is a clinically meaningful milestone, because patients who progress early fare substantially worse and may benefit from different surveillance intensity or earlier therapeutic intervention. By demonstrating the value of combining host inflammatory biomarkers with established clinical prognostic factors, the study shows how cheap, widely available measures can refine risk stratification and individualize follow-up strategies without requiring expensive genomic testing in every patient.

Collectively, the six articles reveal overarching themes that are defining the future of lymphoma research. Molecular characterization is becoming fundamental to clinical decision-making, enabling therapies to be matched to specific biological alterations. Immunotherapy continues to expand beyond conventional monoclonal antibodies through immune checkpoint inhibitors, bispecific antibodies, immunomodulatory drugs, and cellular therapies. Understanding the biological mechanisms responsible for therapeutic resistance is essential for designing more durable treatment strategies. And advances in prognostic biomarkers and predictive models are improving clinicians’ ability to tailor both treatment and follow-up to patient-specific risk. Substantial challenges remain, however: many promising molecular targets require validation in prospective multicenter studies, and predictive biomarkers must demonstrate reproducibility across diverse patient populations before they can guide care.

The path forward will depend on continued collaboration between basic scientists, translational investigators, and clinicians, and on the integration of comprehensive molecular profiling, multi-omic technologies, artificial intelligence, and biomarker-driven clinical trial designs. As precision hematology continues to evolve, the identification of novel molecular targets, validated biomarkers, and effective combination therapies will be instrumental in achieving more durable responses and better outcomes for patients with low-grade non-Hodgkin lymphoma. What the Research Topic makes clear is that personalized treatment is no longer a distant aspiration but an emerging reality, built study by study, target by target, and patient by patient.

Subject of Research: Molecular targets and personalized therapy for low-grade non-Hodgkin lymphoma

Article Title: Editorial: New molecular targets for personalized treatment for low-grade non-hodgkin lymphoma

Article References: Editorial: New molecular targets for personalized treatment for low-grade non-hodgkin lymphoma. (n.d.). https://doi.org/10.3389/frhem.2026.1959952

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1959952

Keywords: low-grade non-Hodgkin lymphoma, precision medicine, EZH2, PD-L1, Waldenström macroglobulinemia, bispecific antibodies, glofitamab, MYD88, CXCR4, drug resistance, follicular lymphoma, prognostic biomarkers